> Research Use Only Disclaimer: GHRP-2 (pralmorelin) has not been approved by the FDA for human therapeutic use. It is approved in Japan as Pralmorelin® for GH deficiency diagnostic testing. Outside Japan, GHRP-2 is available only as a research chemical. This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
---
What Is GHRP-2?
GHRP-2 (Growth Hormone-Releasing Peptide-2), marketed in Japan under the brand name Pralmorelin, is a synthetic hexapeptide growth hormone secretagogue with the sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂. It belongs to the growth hormone-releasing peptide (GHRP) family — a class of synthetic enkephalin-derived compounds developed by Cyril Y. Bowers and colleagues beginning in the late 1970s.
GHRP-2 is the second-generation GHRP, designed to improve upon the original GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) with modifications that:
- •Increase potency (approximately 3–5× more potent than GHRP-6 in GH-release assays)
- •Reduce the appetite-stimulating side effects characteristic of GHRP-6
- •Improve metabolic stability
Regulatory status:
- •Japan: Approved by Japan's Ministry of Health, Labour and Welfare (MHLW) in 2001 as a diagnostic agent for growth hormone deficiency (marketed as Pralmorelin®)
- •USA/EU/Global: Not FDA/EMA approved; available as a research chemical
The Japanese regulatory approval is significant — it makes GHRP-2 the only synthetic GHRP with full regulatory approval anywhere in the world, providing a body of clinical pharmacology data that informs research applications.
---
Historical Context: Discovery of GHRPs
The GHRP family was discovered through systematic research at Tulane University by Cyril Yohan Bowers, who observed in the 1970s that certain synthetic enkephalin analogs with no opioid activity could nonetheless stimulate GH release from pituitary cells in culture. This was paradoxical because endogenous opioids suppress GH secretion.
Further structural optimization produced GHRP-6 (the prototype hexapeptide), then GHRP-1, and eventually GHRP-2. When the receptor for these compounds was cloned in 1996 — the growth hormone secretagogue receptor (GHS-R) — it became clear that an endogenous ligand must exist. That ligand, ghrelin, was discovered in 1999, retroactively explaining the GHRPs' mechanism of action. GHRPs are thus synthetic ghrelin mimetics that preceded the discovery of ghrelin itself.
This history establishes GHRP-2 as part of one of the most consequential serendipitous discoveries in peptide endocrinology: the synthetic GHRPs led directly to the identification of the ghrelin system, a fundamental regulator of energy metabolism and GH secretion.
---
Mechanism of Action
GHS-R1a Agonism
GHRP-2 is a full agonist at GHS-R1a (growth hormone secretagogue receptor 1a), the canonical ghrelin receptor. This class B-adjacent GPCR couples primarily to Gαq/PLCβ/IP₃/DAG signaling:
1. Gαq activation stimulates phospholipase Cβ (PLCβ)
2. IP₃ releases calcium from endoplasmic reticulum stores
3. DAG activates protein kinase C (PKC)
4. Calcium surge and PKC act synergistically to trigger GH secretory granule fusion and exocytosis
GHS-R1a is expressed in the pituitary somatotrophs (primary site for GH release), the hypothalamus (where GHRP-2 also stimulates GHRH release and inhibits somatostatin), and in peripheral tissues including heart, adrenal cortex, and the gastrointestinal tract.
GHRH Synergy — The Dual-Action Mechanism
GHRP-2 does not act on pituitary somatotrophs in isolation. It has two complementary actions:
Pituitary level (direct):
- •GHS-R1a activation on somatotrophs directly stimulates GH release (even from isolated pituitary cells in vitro)
Hypothalamic level (indirect):
- •GHS-R1a in the hypothalamus amplifies endogenous GHRH release from arcuate nucleus neurons
- •GHS-R1a reduces somatostatin (SRIH) release from periventricular neurons
This dual action explains why GHRP-2 + GHRH/GHRH-analog combinations produce synergistic GH release — estimated at 3–5× greater than the additive effect of either compound alone. The synergy is mechanistically distinct from simple additive effects because GHRP-2 removes the somatostatin brake while GHRH simultaneously pushes the Gαs/cAMP/PKA pathway.
Cortisol and Prolactin Effects
A key pharmacological feature of GHRP-2 (shared with other GHRPs) is stimulation of cortisol and prolactin secretion in addition to GH. This occurs via GHS-R1a in:
- •Adrenal cortex (direct cortisol stimulation)
- •Pituitary lactotrophs (prolactin release)
Cortisol and prolactin elevations with single GHRP-2 doses are typically modest and transient, but they represent a pharmacological distinction from ipamorelin — which is highly selective for GH release with minimal cortisol/prolactin effects. For research protocols where cortisol/prolactin confounders must be minimized, ipamorelin may be preferred. For protocols explicitly studying the full GHS-R1a pharmacological profile, GHRP-2 is appropriate.
---
Comparison: GHRP-2 vs GHRP-6 vs Ipamorelin
| Parameter | GHRP-2 | GHRP-6 | Ipamorelin |
|---|---|---|---|
| Sequence | D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂ | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Generation | 2nd | 1st | 3rd |
| GH potency | High | Moderate | Moderate-high |
| Appetite stimulation | Moderate | Strong | Minimal |
| Cortisol elevation | Moderate | Moderate | Minimal |
| Prolactin elevation | Moderate | Moderate | Minimal |
| Regulatory approval | Japan (diagnostic) | None | None |
| Research selectivity | Broad GHS pharmacology | Appetite/GH coupling | GH-selective |
For a comprehensive GHRP comparison see: GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin and Ipamorelin vs GHRP-2 comparison.
---
Key Research Studies
Bowers CY 1998 — Comprehensive GHRP Pharmacology (PMID 9893708)
The landmark review by Cyril Bowers in Cell and Molecular Life Sciences (1998;54:1316-29) synthesized decades of GHRP research, documenting GHRP-2's potent and reproducible GH-releasing activity across species, its hypothalamic-pituitary mechanism, and its distinction from the GHRH pathway. This paper established the mechanistic framework that subsequent ghrelin research built upon.
Japan GHD Diagnostic Approval Studies
Studies supporting pralmorelin's approval in Japan demonstrated that intravenous GHRP-2 at 1–2 μg/kg produces a robust, reproducible GH response in GH-sufficient individuals (peak GH >6 ng/mL) that is markedly blunted in patients with GHD (peak GH <6 ng/mL). This GH stimulation test has become an established diagnostic tool in Japan, comparable to insulin tolerance testing or GHRH+arginine tests used elsewhere.
GHRP-2 in Growth Hormone-Deficient Children (PMID 14513874)
An 8-week study of oral GHRP-2 administration (Capromorelin) in GHD children examined changes in appetite and body weight. While GHRP-2 is primarily given subcutaneously in diagnostic settings, this research demonstrated appetite stimulation as a measurable secondary endpoint — consistent with GHS-R1a activation in hypothalamic feeding centers.
GHRP-2 and ACTH/Cortisol Stimulation (PMID 19682503)
Research characterizing GHRP-2's effect on the HPA axis demonstrated significant stimulation of ACTH and cortisol secretion from mouse pituitary cells — confirming that GHS-R1a agonism extends beyond pure GH secretagogue effects to encompass broader anterior pituitary and adrenal responses. This finding is critical for designing controlled research protocols.
GH Secretagogue Treatment in Hypogonadal Men (PMID 28830317)
A clinical study in hypogonadal men treated with GH secretagogues (including GHRP-2) demonstrated significant increases in serum IGF-1 levels vs. placebo, supporting the concept that GHS-R1a agonists can meaningfully amplify GH axis output in populations with suboptimal baseline GH secretion.
Synergy Studies: GHRP-2 + GHRH
Multiple research groups have documented 3–5× synergistic GH amplification when GHRP-2 is combined with GHRH or CJC-1295 compared to either compound alone. This synergy forms the research basis for combination stack protocols in GH axis research.
---
Research Applications
GHRP-2 is used in research settings to:
- •GH deficiency testing (via pralmorelin stimulation test — standard in Japan)
- •GHS-R1a pharmacology — studying the ghrelin receptor's full signaling repertoire
- •Appetite and metabolic research — exploring ghrelin axis effects on food intake and energy metabolism
- •GH/IGF-1 axis studies — dose-response characterization across animal models
- •Comparison pharmacology — baseline GHRP for comparing newer selectivity profiles (ipamorelin, hexarelin)
- •Neuroendocrine research — HPA axis modulation via GHS-R1a
---
Sourcing & Price Comparison (2026 Live Data)
| Supplier | Price/mg | Product |
|---|---|---|
| Pure Peptides UK | $1.90/mg | CJC+GHRP-2 blend, 5 mg |
| Pure Peptides UK (Premium) | $3.20/mg | Premium GHRP-2 5 mg |
| Biotech Peptides | $3.90/mg | GHRP-2 10 mg |
> Note: GHRP-2 is among the most affordable research peptides in the GH secretagogue class. Live pricing for individual supplier products is available via Peptides.SO GHRP-2 peptide page. See also: GHRP-2 dosage protocol guide.
---
Frequently Asked Questions
Q: Why is GHRP-2 called "pralmorelin" in Japan?
A: Pralmorelin is the International Nonproprietary Name (INN) assigned to GHRP-2 when it received regulatory approval in Japan in 2001 for diagnostic use in GH deficiency. The GHRP-2 designation is used in research literature; pralmorelin is the regulatory/pharmaceutical name for the same molecule.
Q: How does GHRP-2 compare to ipamorelin for research?
A: GHRP-2 is more potent than ipamorelin in GH release and additionally stimulates cortisol and prolactin. Ipamorelin is more selective, producing GH release with minimal cortisol/prolactin effects. For research studying the full GHS-R1a pharmacological profile, GHRP-2 is appropriate. For research focused solely on GH/IGF-1 effects without HPA axis confounders, ipamorelin may be preferred. See Ipamorelin vs GHRP-2.
Q: Is GHRP-2 synergistic with GHRH analogs?
A: Yes. The combination of GHRP-2 with GHRH analogs (sermorelin, CJC-1295, etc.) produces 3–5× greater GH release than either compound alone. This synergy is mechanistically explained by GHRP-2's dual action: it directly stimulates somatotrophs via GHS-R1a while also amplifying hypothalamic GHRH release and reducing somatostatin inhibition. Combined stacks are commonly used in GH axis research.
Q: Does GHRP-2 desensitize GHS-R1a receptors?
A: Chronic GHRP-2 administration produces some degree of receptor downregulation, though this is less pronounced than with hexarelin (the most potent GHRP, which shows the most tachyphylaxis). Research protocols typically include off-cycle periods to allow receptor resensitization. The intermittent pulsatile dosing schedule (mimicking natural ghrelin pulsatility) minimizes desensitization compared to continuous infusion.
Q: What were the key findings from the Japan pralmorelin approval?
A: The diagnostic test showed that 1–2 μg/kg IV pralmorelin reliably stimulates a peak GH response >6 ng/mL in GH-sufficient individuals and <6 ng/mL in GHD patients. Test sensitivity and specificity were comparable to standard provocative tests (insulin tolerance test, glucagon). The test has shorter duration than insulin tolerance testing and avoids hypoglycemia risk, making it preferable in certain patient populations.
Q: Can GHRP-2 affect appetite in research models?
A: Yes. GHS-R1a is expressed in the hypothalamic arcuate nucleus, where it colocalizes with NPY/AgRP neurons. GHRP-2 activation at these sites stimulates feeding behavior and food intake in animal models. This appetite effect is more pronounced than with ipamorelin but somewhat less pronounced than with GHRP-6. It is a relevant variable in body composition and metabolic research protocols.
---
Disclaimer
This article is for educational and research informational purposes only. GHRP-2 (pralmorelin) is not approved by the FDA for human therapeutic use. All information reflects published scientific literature and does not constitute medical advice. Researchers should comply with all applicable regulations in their jurisdiction. For Research Use Only — Not for Human Consumption.
---
Related articles: GHRP-6 Research Profile 2026 · Hexarelin Research Profile 2026 · Ipamorelin Research Profile 2026 · GHRPs Compared